• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
Senology.org Newsletter - April 3, 2012
 

Senology.org Newsletter - April 3, 2012

on

  • 297 views

Latest Advances in Clinical Senology and Oncology

Latest Advances in Clinical Senology and Oncology

Statistics

Views

Total Views
297
Views on SlideShare
297
Embed Views
0

Actions

Likes
0
Downloads
0
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    Senology.org Newsletter - April 3, 2012 Senology.org Newsletter - April 3, 2012 Document Transcript

    • Senology Newsletter Page 1 of 3 Senology.org - Newsletter International Senologic and Oncologic  Scientific Community (ISOSC)  "Connecting specialists worldwide" Editor-in-Chief: Gian Paolo Andreoletti, MD Subscribe Unsubscribe Contact Back Issues Connecting Specialists Worldwide SENOLOGY GROUP on LiINKEDIN now has more than 1000 MEMBERS! JOIN US! Join us on LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare, Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for real-time updates Literature Selection Sechopoulos I et al.: "Mammography and the risk of thyroid cancer", AJR Am J Roentgenol. 2012 Mar;198(3):705-7 Pritchard KI et al.: "Prospective Study of 2-[18F]Fluorodeoxyglucose Positron Emission Tomography in the Assessment of Regional Nodal Spread of Disease in Patients With Breast Cancer: An Ontario Clinical Oncology Group Study", J Clin Oncol. 2012 Mar 5. [Epub ahead of print] Riegger C et al.: "Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients", Eur J Nucl Med Mol Imaging. 2012 Mar 6. [Epub ahead of print] Allred DC et al.: "Adjuvant Tamoxifen Reduces Subsequent Breast Cancer in Women With Estrogen Receptor-Positive Ductal Carcinoma in Situ: A Study Based on NSABP Protocol B-24", J Clin Oncol. 2012 Mar 5. [Epub ahead of print] Regan MM et al.: "CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial", J Natl Cancer Inst. 2012 Mar 6. [Epub ahead of print] Trovo M et al.: "Locoregional Failure in Early-Stage Breast Cancer Patients Treated with Radical Mastectomy and Adjuvant Systemic Therapy: Which Patients Benefit from Postmastectomy Irradiation?", Int J Radiat Oncol Biol Phys. 2012 Mar 2. [Epub ahead of print] Wang SY et al.: "Network Meta-analysis of Margin Threshold for Women With Ductal Carcinoma In Situ", J Natl Cancer Inst. 2012 Mar 22. [Epub ahead of print] Zhou W et al.: "US-guided Percutaneous Microwave Coagulation of Small Breast Cancers: A Clinical Study", Radiology. 2012 Mar 21. [Epub ahead of print] Bates T et al.: "Primary chemo-radiotherapy in the treatment of locally advanced and inflammatory breast cancer", Breast. 2012 Mar 10. [Epub ahead of print]file://C:Documents and SettingsutenteDesktopNewsl_Apr_2012.htm 03/04/2012
    • Senology Newsletter Page 2 of 3 Oda M et al.: "High levels of DJ-1 protein in nipple fluid of patients with breast cancer", Cancer Sci. 2012 Mar 9.[Epub ahead of print] Calendar of Events 4th IMPAKT Breast Cancer Conference, May 3-5, 2012, Brussels, Belgium 14th Milan Breast Cancer Conference, June 20-22, 2012, Milan, Italy 17th World Congress on Breast Diseases of the Senologic International Society, -SIS, October 10-13, 2012, Salvador, Bahia, Brazil Fragments of History William S Halsted (New York, 1852-1922), "The results of radical operations for the cure of carcinoma of the breast", Ann Surg. July 1907:46(1):1-19": “The Operation - A part of the chest wall should, I believe, be excised in certain cases, the surgeon bearing in mind always that he is dealing with lymphatic and not blood metastases and that the slightest inattention to detail, or attempts to hasten convalescence by such plastic operations as are feasible only when a restricted amount of skin is removed, may sacrifice his patient" Literature Selection Rothwell PM et al.: "Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials", Lancet. 2012 Mar 20. [Epub ahead of print] Lipshultz SE et al.: "Cardiovascular Status of Childhood Cancer Survivors Exposed and Unexposed to Cardiotoxic Therapy", J Clin Oncol. 2012 Mar 5. [Epub ahead of print] Dann RB et al.: "BRCA1/2 mutations and expression: Response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer", Gynecol Oncol. 2012 Mar 8. [Epub ahead of print] Asgari MM et al.: "Association of Vitamin A and Carotenoid Intake with Melanoma Risk in a Large Prospective Cohort", J Invest Dermatol. 2012 Mar 1. doi: 10.1038/jid.2012.21. [Epub ahead of print] Qaseem A et al.: "Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians", Ann Intern Med. 2012 Mar 6;156(5):378-386 Chen Y et al.: "Excess body weight and the risk of primary liver cancer: An updated meta-analysis of prospective studies", Eur J Cancer. 2012 Mar 23. [Epub ahead of print] Silverman DT et al.: "The Diesel Exhaust in Miners Study: A Nested Case-Control Study of Lung Cancer and Diesel Exhaust", J Natl Cancer Inst. 2012 Mar 5. [Epub ahead of print] Attfield MD et al.: "The Diesel Exhaust in Miners Study: A Cohort Mortality Study With Emphasis on Lung Cancer", J Natl Cancer Inst. 2012 Mar 5. [Epub ahead of print] Edelman MJ et al.: "CYFRA 21-1 as a Prognostic and Predictive Marker in Advanced Non-Small-Cell Lung Cancer in a Prospective Trial: CALGB 150304", J Thorac Oncol. 2012 Apr;7(4):649-54 Lang-Lazdunski L et al.: "Pleurectomy/Decortication is Superior to Extrapleural Pneumonectomy in the Multimodality Management of Patients with Malignant Pleural Mesothelioma", J Thorac Oncol. 2012 Apr;7(4):737-43 Wright JL et al.: "Circumcision and the risk of prostate cancer", Cancer. 2012 Mar 12.[Epub ahead of print] Schroder FH et al.: "Prostate-cancer mortality at 11 years of follow-up", N Engl J Med. 2012 Mar 15;366 (11):981-90 Comment "Effects of prenatal exposure to chemotherapy", Frederic Amant, Leuven Cancer Institute, Gynaecologic Oncology, Katholieke Universiteit Leuven, Belgium "We believe that our findings have the potential to change clinical practice in three situations. Firstly, the fear for the negative effects of chemotherapy should not be a reason to terminate pregnancy. Secondly, the fear for chemotherapy should not be a reason to delay maternal treatment. Thirdly, the fear for chemotherapy should not be a reason to decide to deliver the fetus prematurely in order to start chemo after delivery. Regarding the latter, we believe that children suffer more form the long term consequences of prematurity when compared to chemotherapy." (Comment on: Amant F et al.: "Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study", Lancet Oncol. 2012 Feb 9. [Epub ahead of print]) Discussionfile://C:Documents and SettingsutenteDesktopNewsl_Apr_2012.htm 03/04/2012
    • Senology Newsletter Page 3 of 3 - "Study published in The New England Journal of Medicine: PSA-based screening significantly reduces mortality from prostate cancer but doesnt affect all-cause mortality" - Share your opinion on LinkedIn® Literature Selection Anderson GL et al.: "Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Womens Health Initiative randomised placebo-controlled trial", Lancet Oncol. 2012 Mar 6. [Epub ahead of print] Marchbanks PA et al.: "Oral contraceptive formulation and risk of breast cancer", Contraception. 2012 Apr;85(4):342-50 Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the Expert Q&A Workshops and join the conversation. TalkAboutHealth Q&A of the month "What is the current status of using trastuzumab and lapatinib to treat HER-2-positive inflammatory breast cancers?" "The use of trastuzumab plus paclitaxel followed by trastuzumab plus FEC chemotherapy is the standard preoperative systemic therapy for HER2 positive primary inflammatory breast cancer. The role of lapatinib in primary inflammatory breast cancer is unknown despite that there are data suggesting lapatinib may have a response in trastuzumab-resistant HER2 positive metastatic breast cancer. For HER2+ metastatic breast cancer can be treated with lapatinib plus capecitabine, and trastuzumab plus chemotherapy" (Answer by Naoto Tada Ueno, Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA) Stay informed.... Recent Advances in Clinical Medicine Papp KA et al.: "Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis ", N Engl J Med. 2012 Mar 29;366(13):1181-9 Unsubscribe       www.senology.orgfile://C:Documents and SettingsutenteDesktopNewsl_Apr_2012.htm 03/04/2012